Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

ImmuNext, J&J in cancer deal

September 6, 2012 12:39 AM UTC

ImmuNext Inc. (Lebanon, N.H.) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights to develop and commercialize products that antagonize the V-region immunoglobulin-containing suppressor of T cell activation (VISTA). J&J plans to develop immunotherapies for cancer. ImmuNext will receive an upfront payment, plus milestones, which could total more than $150 million. ImmuNext is also eligible for tiered royalties. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article